Human Translational Core
人类翻译核心
基本信息
- 批准号:10395971
- 负责人:
- 金额:$ 26.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AchievementAddressAnimal ModelAnimalsBiological MarkersBiological Specimen BanksBiometryCaliforniaCell Culture TechniquesClinicalCollectionComplementComputerized Medical RecordConsultationsCoupledData AnalysesData Management ResourcesDiagnosisDigestive System DisordersDiseaseEndoscopic BiopsyFaceFecesGastroenterologyGastrointestinal DiseasesHumanIn VitroInflammationInflammatory Bowel DiseasesKnowledgeLeadershipLinkLiverLiver diseasesMetadataNeedle biopsy procedureOnline SystemsOutcomePathogenesisPathologicPatientsPeripheral Blood Mononuclear CellPhenotypePlasmaPre-Clinical ModelProcessResearchResearch DesignResearch PersonnelSample SizeSamplingServicesSystemTestingTissue BanksTissue SampleTissuesTranslational ResearchUniversitiesUpper digestive tract structureWhole Bloodanimal databench to bedsidebiobankchronic liver diseaseclinical phenotypecohortcost effectiveexperiencefunctional genomicsgastrointestinalhuman diseasehuman studyhuman tissueinnovationliver biopsymembermicrobiome researchnon-alcoholic fatty liver diseasephenotypic datapre-clinicalsample collectiontraining opportunitytranslational scientisttranslational study
项目摘要
Summary
The objective of the Human Translational Core is to facilitate bench-to-bedside translational studies by
providing members of the San Diego Digestive Diseases Research Center ready access to human
biospecimens of well-characterized cohorts of patients with digestive diseases. Moreover, The Core will provide
clinical expertise for examining paradigms that emerge from basic studies conducted in animals and in vitro and
relating them to clinical phenotypes seen in patients with digestive diseases. The Core will be led by highly
accomplished clinical and translational researchers from the University of California, San Diego (UCSD) Division
of Gastroenterology, with Dr. Rohit Loomba as Director, Dr. William Sandborn as Co-Director, and Dr. Sheila
Crowe as Co-Investigator. Drs. Loomba and Sandborn have already established modest biorepositories in the
Nonalcoholic Fatty Liver Disease (NAFLD) Center and Inflammatory Bowel Disease (IBD) Center, respectively.
The proposed Core will build on these achievements and markedly expand and streamline the repository of
biospecimens from well-characterized digestive disease patients as well as appropriate controls. Established
strengths of this Core include the outstanding track record of the Core leadership in translational research related
to inflammation in gastrointestinal and liver diseases; their experience in detailed phenotyping of patients with
digestive diseases; access to existing and well-characterized cohorts of patients with specific digestive diseases;
access to a biorepository of existing human biospecimens; synergistic interactions and the availability of state-
of-the-art data management resources; and strong pathological and biostatistical expertise. This Core will
interact with and complement the Preclinical Models and Microbiomics and Functional Genomics Cores by
facilitating research to relate biomarkers and preclinical data from animal models to specific outcomes in patients
with digestive diseases. The Human Translational Core has the following Aims: 1. To collect, process and
annotate human tissue samples, including liver biopsies, endoscopic gastrointestinal tissues, whole blood,
plasma, serum, peripheral blood mononuclear cell (PBMC), and stool; 2. To provide human biospecimens
coupled with patient metadata to Center investigators; 3. To offer clinical, biostatistical and pathological
consultation services, as well as training opportunities. Thus, this Core will benefit the Center members by
providing reliable, cost-effective services for enhancing the scope and innovation of their research and its
relevance to human diseases of the digestive tract.
概括
人类翻译核心的目标是通过以下方式促进实验室到临床的转化研究:
为圣地亚哥消化疾病研究中心的成员提供随时接触人类的机会
特征明确的消化系统疾病患者群体的生物样本。此外,Core 将提供
用于检查在动物和体外进行的基础研究中出现的范式的临床专业知识
将它们与消化系统疾病患者的临床表型联系起来。核心将由高层领导
来自加州大学圣地亚哥分校 (UCSD) 部门的临床和转化研究人员
胃肠病学系,Rohit Loomba 博士担任主任,William Sandborn 博士担任联合主任,Sheila 博士
克罗担任联合研究员。博士。 Loomba 和 Sandborn 已经在
分别是非酒精性脂肪肝 (NAFLD) 中心和炎症性肠病 (IBD) 中心。
拟议的核心将建立在这些成就的基础上,并显着扩展和简化知识库
来自特征明确的消化系统疾病患者的生物样本以及适当的对照。已确立的
该核心的优势包括核心在转化研究相关领域的领导力的杰出记录
胃肠道和肝脏疾病的炎症;他们对患者进行详细表型分析的经验
消化系统疾病;接触现有且特征明确的特定消化系统疾病患者队列;
获取现有人类生物样本的生物储存库;协同相互作用和状态的可用性
最先进的数据管理资源;以及强大的病理和生物统计学专业知识。该核心将
与临床前模型、微生物组学和功能基因组学核心相互作用并补充
促进将动物模型的生物标志物和临床前数据与患者的特定结果联系起来的研究
患有消化系统疾病。人类翻译核心有以下目标: 1. 收集、处理和
注释人体组织样本,包括肝活检、内窥镜胃肠组织、全血、
血浆、血清、外周血单核细胞 (PBMC) 和粪便; 2. 提供人体生物样本
向中心研究人员提供患者元数据; 3. 提供临床、生物统计和病理学
咨询服务以及培训机会。因此,该核心将使中心成员受益
提供可靠、具有成本效益的服务,以扩大其研究及其研究的范围和创新
与人类消化道疾病的相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROHIT LOOMBA其他文献
ROHIT LOOMBA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROHIT LOOMBA', 18)}}的其他基金
Role of liver fat and fibrosis in human CVD risk phenotypes.
肝脏脂肪和纤维化在人类心血管疾病风险表型中的作用。
- 批准号:
10683992 - 财政年份:2020
- 资助金额:
$ 26.9万 - 项目类别:
Role of liver fat and fibrosis in human CVD risk phenotypes.
肝脏脂肪和纤维化在人类心血管疾病风险表型中的作用。
- 批准号:
10262921 - 财政年份:2020
- 资助金额:
$ 26.9万 - 项目类别:
Role of liver fat and fibrosis in human CVD risk phenotypes.
肝脏脂肪和纤维化在人类心血管疾病风险表型中的作用。
- 批准号:
10461067 - 财政年份:2020
- 资助金额:
$ 26.9万 - 项目类别:
Non-invasive screening of diabetics for advanced fibrosis due to NAFLD
对糖尿病患者进行 NAFLD 引起的晚期纤维化的无创筛查
- 批准号:
10392426 - 财政年份:2020
- 资助金额:
$ 26.9万 - 项目类别:
Non-invasive screening of diabetics for advanced fibrosis due to NAFLD
对糖尿病患者进行 NAFLD 引起的晚期纤维化的无创筛查
- 批准号:
10166841 - 财政年份:2020
- 资助金额:
$ 26.9万 - 项目类别:
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD
用于 NAFLD 肝脂肪变性诊断和分级的 QUS 技术
- 批准号:
9070671 - 财政年份:2015
- 资助金额:
$ 26.9万 - 项目类别:
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD
用于 NAFLD 肝脂肪变性诊断和分级的 QUS 技术
- 批准号:
8945356 - 财政年份:2015
- 资助金额:
$ 26.9万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
IgG and FcR Characterization in Small Animal Models of RespiratoryDisease
呼吸道疾病小动物模型中的 IgG 和 FcR 表征
- 批准号:
10678229 - 财政年份:2023
- 资助金额:
$ 26.9万 - 项目类别:
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strains
了解抗体反应并定义地方性和大流行性冠状病毒株保护的相关性
- 批准号:
10549479 - 财政年份:2023
- 资助金额:
$ 26.9万 - 项目类别:
Restoration of Muscular Function Following Direct Muscle Neurotization
直接肌肉神经化后肌肉功能的恢复
- 批准号:
10699345 - 财政年份:2023
- 资助金额:
$ 26.9万 - 项目类别:
EPR scanner for tumor oximetry in the clinic
用于临床肿瘤血氧测定的 EPR 扫描仪
- 批准号:
10586942 - 财政年份:2023
- 资助金额:
$ 26.9万 - 项目类别: